Final Glance: Biotechnology companies
AP - Fri Jun 27, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Midday Glance: Biotechnology companies
AP - Fri Jun 27, 12:33PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Early Glance: Biotechnology companies
AP - Fri Jun 27, 9:26AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 10 a.m.:
CORRECTING and REPLACING Celgene Corporation Mourns the Passing of Board of Director Member, Rodman L. Drake
Business Wire - Thu Jun 26, 1:28PM CDT
Third paragraph, second sentence has been deleted because of redundancy.
Companies Chasing Gold Nugget of Immuno-Oncology Like Never Before
ACCESSWIRE - Thu Jun 26, 8:37AM CDT
WHITEFISH, MT / June 26, 2014 / Probably the most explosive field in biotechnology right now is that of immuno-oncology. The field is predicated on the concept that the body's immune system can be augmented or taught to modulate cancer without the use of toxic chemotherapy agents and radiation, the standard of care today worldwide. A few years ago, the immuno-oncology research was relatively non-existent, but now it's one of the hottest around with some big pharmas making it a primary directive. Last year, Merck & Co. (NYSE: MRK) brought back Roger Perlmutter, a man with an extensive background in immunology, for a second tour with the company, this time as EVP and President of Merck Research Laboratories, to shepherd a new path for Merck focused on oncology at the research level with an emphasis on immuno-oncology. Last week, Merck enlisted MorphoSys AG in a partnership to develop therapeutic antibodies against immune checkpoints. The antibody experts at MorphoSys are in high demand, inking development agreements with Celgene (NASDAQ: CELG), GlaxoSmithKline (NYSE: GSK), Novartis (NYSE: NVS) and more to develop antibodies to support the human immune system against cancer.
Celgene Corporation Mourns the Passing of Board of Director Member, Rodman L. Drake
Business Wire - Thu Jun 26, 7:30AM CDT
It is with great sadness that Celgene Corporation (NASDAQ:CELG) announces the death of Rodman L. Drake, a member of its Board of Directors since 2006.
'Fast Money' Recap: A Mixed Bag for Housing
at The Street - Wed Jun 25, 4:00AM CDT
The trading panel discussed the stock market's big drop, how low the S&P can go and why bonds aren't selling off.
Celgene, Chipotle, Keurig Remain In Buying Range
at Investor's Business Daily - Mon Jun 23, 6:52PM CDT
This week's Big Cap 20 list showed a few changes from last week, as Apple (AAPL), Encana (ECA) and Magna International (MGA) fell out and were replaced by Celgene (CELG), Spectra Energy (SE) and Southwest Airlines (LUV) . Energy plays still dominate...
Stocks Poised For Soft Start; Micros Systems Surges Premarket
at Investor's Business Daily - Mon Jun 23, 7:56AM CDT
The stock market today appeared poised for a mildly lower start despite upbeat Chinese factory data and a round of deal news. Nasdaq 100 futures fell 2 points vs. fair value, while S&P 500 futures edged down less than 1 point. Dow futures lost 12...
Celgene Sees Better Results For Psoriatic Arthritis
at Investor's Business Daily - Fri Jun 20, 5:12PM CDT
When a large biotechnology company has a wonder drug, it makes sense to see if the product can treat multiple diseases. Celgene (CELG) has done well in this regard. In January, Celgene's key drug Abraxane won approval in Europe for use in combination...
Stocks Hold Slim Gains; Celgene, Salix Rally
at Investor's Business Daily - Fri Jun 20, 2:02PM CDT
The major stock indexes continued to trade modestly higher late Friday and were on pace to end the week with gains of more than 1%. The Dow Jones industrial average rose 0.2%. The broader Nasdaq and the S&P 500 edged up 0.1% each. Amid quadruple...
Celgene (CELG) Approaches New Upside Target of $171.95
Comtex SmarTrend(R) - Fri Jun 20, 12:28PM CDT
Celgene (NASDAQ:CELG) has opened bullishly above the pivot of $166.67 today and has reached the first level of resistance at $170.13. Investors may be interested in a cross of the next upside pivot targets of $171.95 and $177.23.